Compare Newegg Commerce Inc (NEGG) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Newegg Commerce Inc vs Recursion Pharmaceuticals Inc — how do they compare? Newegg Commerce Inc trades at $11.58 (market cap $243.30M), while Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 8.8× Newegg Commerce Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Newegg Commerce Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Newegg Commerce Inc for 14 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| NEGG | RXRX | |
|---|---|---|
Market Cap | $243.30M | $2.14B |
Volume | 41,252 | 30,789,535 |
Sector | Consumer Cyclical | Health |
52-Week High | $92.74 | $6.79 |
52-Week Low | $11.49 | $2.84 |
Typical Hold Time | 14 Days | 23 Days |
Enterprise Value | $213.53M | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NEGG trades at $11.58, down 3.58% on the day, with a bearish technical signal from moving averages but oversold RSI readings. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $0.11 versus a -$0.40 estimate. The company shows improving fundamentals, with revenue stabilizing around $1.4B and net losses narrowing significantly in 2025. New partnerships with Western Digital and Hewlett Packard Enterprise highlight strategic moves in IT infrastructure.
The outlook is mixed; improving profitability and low P/S ratio offer value, but negative operating cash flow and insider selling pose risks. Analyst consensus is a Buy with a $7.75 target, below the current price, indicating caution. Key risks include competitive pressures and reliance on financing activities for liquidity.
RXRX trades at $4.36, up 2.11% today, with technical indicators showing a bullish trend. The company reported Q3 2026 revenue of $54 million but continues to post significant losses with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche are expanding its AI-driven drug pipeline, though the stock faces high short interest and substantial cash burn from operations.
The outlook remains speculative given persistent losses and high valuation multiples (P/S 37.14), but analyst consensus leans positive with 40% buy ratings. Key risks include execution on drug development timelines and dependence on financing activities to fund operations. Upside potential hinges on successful clinical milestones from its expanding pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Newegg Commerce Inc
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services globally.
Read more on NEGG →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
